{"id": "1adc970c-d433-44d0-aa09-d3834986f7a2", "result": "Contradiction.\n\nThe statement is not correct. The difference between the two groups is actually 1 percentage point (89% for anastrozole minus 88% for exemestane), which is a relative difference of about 1.12% (1/88 \\* 100). This is not the same as a 13.2% difference as stated."}
{"id": "6b9162d0-0816-46d4-81af-c60028dcc63b", "result": "Contradiction.\n\nThe statement is not correct. The primary trial excludes patients with cardiac left ventricular function with resting ejection fraction < 50% (below upper limit of normal), while the secondary trial does not mention any exclusion criteria based on ejection fraction. However, the secondary trial does not limit eligibility to patients who are 55 years of age or over, so there is no requirement that patients with a lower ejection fraction would be eligible for the secondary trial."}
{"id": "0b6cc8e3-69ee-4a91-b93d-2ad3fddce65f", "result": "Contradiction.\n\nThe statement is not correct. The primary trial reports a total of 3 adverse events of enterocolitis among 167 participants (1.8%), while the secondary trial reports a total of 0 adverse events of enterocolitis among 458 participants (0.0%). Therefore, it is not accurate to say that a significant number of participants in either trial suffered from enterocolitis."}
{"id": "cc1f712a-2116-4e40-9810-f315e3fa5ff8", "result": "Entailment.\n\nThe statement is correct. The primary trial results section provided does not report the progression-free survival (PFS) or objective response rate (ORR) of its patient cohort. The trial measures local control using ipsilateral breast tumor recurrence rates, and the result reported is the percentage of participants with an event-free survival of 0.7%. The trial may have reported PFS or ORR in other sections of the paper or as secondary outcomes, but based on the information provided in the Results section, the statement is true."}
{"id": "904061c0-14fa-4f13-9118-9a41e24fa8eb", "result": "Entailment.\n\nThe statement is true according to the eligibility criteria provided for the primary trial. There is no mention in the criteria that prior treatment with fulvestrant or a PI3K inhibitor would prevent a patient from participating in the trial."}
{"id": "43ee7645-ce1e-42d5-9a74-3e379f6f367b", "result": "Contradiction.\n\nThe statement is not entailed by the given primary trial eligibility criteria. In fact, the primary trial eligibility criteria allow patients with unknown HER2 status and for whom determination of HER2 status is not possible to participate in the trial. Additionally, the eligibility criteria do not specify that only patients with HER2-positive status can take part in the primary trial. Therefore, the statement is not true based on the given information."}
{"id": "0cef8c8e-7986-46c7-a597-c5733a9899c0", "result": "The statement is contradiction.\n\nAccording to the Results section, the shortest PFS in cohort 1 was 7.1 months (95% Confidence Interval [CI]: 5.6 to 10.8) and in cohort 2 was 9.1 months (95% CI: 6.8 to 10.8). Therefore, the shortest PFS in cohort 1 was over 7 months, not under 7 months, and in cohort 2 was just over 7 months, not just over 7 months.\n\nTherefore, the statement is incorrect and is a contradiction to the given trial information."}
{"id": "43ce26e5-03fa-4e9d-b0eb-6ea356295753", "result": "Contradiction.\n\nBased on the given Intervention section, cohort 1 (HER2+ TC) undergoes a total of 17 cycles of treatment, while cohort 2 (HER2+ C) undergoes a total of 10 cycles of treatment. Therefore, the statement that both cohorts undergo a total of 17 cycles of treatment is not correct."}
{"id": "3facad41-0221-42f8-834d-470e65c4aad5", "result": "Contradiction.\n\nThe outcome measurement of the primary trial is Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen, not The length of Time During and After the Treatment that a Patient Survives with the Disease."}
{"id": "9cbc00e9-3a2d-4471-a93e-72c95132fb6a", "result": "Contradiction.\n\nThe statement is not entailed by the provided information. The first adverse events section includes one case of congestive heart failure in cohort 1, but the second adverse events section includes zero cases of congestive heart failure in cohort 2. Therefore, it cannot be concluded that the only case of congestive heart failure in the trial occurred in cohort 1. The provided information does not specify if the total number of participants analyzed in Adverse Events 1 and Adverse Events 2 refers to the total number of participants in the trial or just the number of participants in each cohort."}
{"id": "8b91cab9-d858-45f3-bf8d-3d6fc55b4818", "result": "Contradiction.\n\nThe primary trial results section reports the proportion of sentinel lymph nodes (SLNs) flagged by the two methods, but the two measurements reported are not comparable. The first measurement is the proportion of SLNs detected by the Tc method, and the second measurement is the proportion of SLNs detected by the ICG method. These two measurements are not comparable because they are expressed as proportions of different denominators (N). To ensure a fair comparison, the same denominator (N) should be used in both measurements."}
{"id": "4a75574c-fa86-4e62-a210-81c7b98a3807", "result": "Contradiction.\n\nT4 patients are not eligible for the primary trial. The trial only allows T1-3, N0-2, M0 patients, and T4 patients are not included in this range."}
{"id": "d0b50aeb-aad8-4a8d-aae6-5c58a7d382c7", "result": "Contradiction.\n\nThe primary trial results section reports the proportion of sentinel lymph nodes (SLNs) flagged by the two methods, but it does not specify which cohort the results are for. The results are reported for all three cohorts combined, not for each cohort separately."}
{"id": "b0b61978-57db-4a1c-812c-509e8b05f2dc", "result": "Entailment.\n\nThe two cohorts of the primary trial do receive identical interventions, with the difference being the types of cancer that the patients have. The first cohort, TNBC, is treated with Nivolumab and Daratumumab, and the second cohort, NSCLC, is also treated with Nivolumab and Daratumumab. The only difference between the two cohorts is the type of cancer that the patients have."}
{"id": "24b85b44-b9e6-4c28-b3aa-1bd97102b7f1", "result": "Contradiction.\n\nThe statement that patients must have a palpable carcinoma to be included in the primary trial is not entailed by the eligibility criteria. In fact, the eligibility criteria for phase 2 of the trial specifically state that patients with a non-palpable neoplasm but a palpable hematoma from core biopsy are eligible for the study."}
{"id": "fbb62216-2cf2-4813-ad41-12a86940610f", "result": "Contradiction.\n\nThe statement is not entailed by the provided information. The frequency of anaemia in cohort 1 was 3.52% and in cohort 2 was 5.56%, which is not the same. Therefore, anaemia was not the most common adverse event in both cohorts."}
{"id": "961a956e-fece-4baa-a2ad-d3a5320bd9d2", "result": "Contradiction.\n\nThe statement that the shortest PFS in cohort 1 of the primary trial was less than 3 weeks is not entailed by the results. The median PFS in cohort 1 was 8.4 months (95% CI: 7.0-9.9), which is greater than 3 weeks."}
{"id": "97fd111c-6969-43ab-93af-b3dff09960e5", "result": "Contradiction.\n\nThe statement that the adverse events section in the primary trial is reporting the incidence rate of 12 different AEs is not entailed by the given information. The adverse events section in the primary trial does not provide the incidence rate of any adverse event. It only reports the total number of adverse events in cohort 1."}
{"id": "eb1bfb08-eba0-4130-b328-00f56c0f84a6", "result": "Contradiction.\n\nThe statement that diarrhea is the most common adverse event in both the primary and secondary trials is not entailed by the given information. According to the primary trial, diarrhea occurred in 7.69% (5/65) of the participants, whereas according to the secondary trial, diarrhea occurred in 36.65% (173/472) of the participants. Therefore, diarrhea was not the most common adverse event in both trials."}
{"id": "b1219e71-fbf5-4bba-8a93-a27ae444e3e1", "result": "Entailment.\n\nThe statement is entailed by the given trial information. The inclusion criteria for the primary trial states that patients must have confirmed hormone receptor positive advanced breast cancer, and the exclusion criteria states that patients cannot have received any previous treatment for advanced breast cancer. Therefore, patients must be diagnosed with hormone receptor positive advanced breast cancer but cannot have received any previous treatment for this advanced cancer to be eligible for the primary trial."}
{"id": "f10f3b84-e039-4a02-a98b-86d149d9a16f", "result": "Entailment.\n\nThe statement \"ongoing flucytosine treatments are not permitted for participants of the primary trial\" is entailed by the eligibility criteria of the primary trial. The exclusion criteria of the primary trial explicitly states that patients who are being treated with other pyrimidine fluoride antineoplastic agents, including flucytosine, are not eligible for the trial. Therefore, if a patient is currently receiving flucytosine, they would not be eligible for the primary trial."}
{"id": "0ddb07ae-6e70-436d-8723-f609e59c57da", "result": "Entailment.\n\nThe statement that the primary trial participants receive doses of Pralatrexate that are calculated based on bodyweight is entailed by the given trial information. The intervention section of the primary trial states that the study drug Pralatrexate is administered at a dose of 190 mg/m^2 for 2 to 4 weeks. The \"m^2\" in the dose indicates that the dose is calculated based on the surface area of the participant's body. This surface area is calculated using the square of the participant's height and their weight, so the dose is indeed calculated based on the participant's bodyweight."}
{"id": "c10eea1a-5768-442d-ae07-20b4f8f4b583", "result": "Contradiction.\n\nThe statement \"Only patients with triple negative breast cancer are eligible for the primary trial\" is not entailed by the given information. The eligibility criteria for the primary trial do not specify that patients must have triple negative breast cancer to be eligible. In fact, the eligibility criteria state that patients must have hormone receptor positive advanced breast cancer, which could include HER-2 positive BC. Therefore, not only patients with triple negative breast cancer are eligible for the primary trial."}
{"id": "2ef186d0-b4ab-44de-b785-a63e9e95851a", "result": "Entailment.\n\nThe statement \"most participants in the secondary trial and the primary trial did not suffer from Enterocolitis\" is entailed by the given information. According to the primary trial, 1/167 (0.60%) patients suffered from Enterocolitis, and 0/167 (0.00%) patients suffered from Enterocolitis haemorrhagic. According to the secondary trial, 0/221 (0.00%) patients suffered from Enterocolitis, and 0/221 (0.00%) patients suffered from Enterocolitis haemorrhagic. Therefore, most participants in both trials did not suffer from Enterocolitis."}
{"id": "fef5aedb-21c0-4130-b8a3-cb1df5017c7a", "result": "Entailment.\n\nThe statement \"The adverse events section in the primary trial is empty\" is entailed by the given information. The adverse events section of the primary trial does not list any adverse events, indicating that no adverse events were recorded during the trial."}
{"id": "2655c892-216e-4b96-a8f2-6f64403215c5", "result": "Contradiction.\n\nThe statement \"there were 4 types of Adverse events which did not affect any of the patients in cohort 1 of the primary trial\" is not entailed by the given information. The adverse events section of the primary trial states that the total number of adverse events in cohort 1 was 4/65 (6.15%). Therefore, not all adverse events in cohort 1 did not affect any of the patients."}
{"id": "2825d63b-8f22-4fb8-829f-9567845251c6", "result": "Contradiction.\n\nThe statement \"adults and children can take part in the primary trial\" is not entailed by the given information. The eligibility criteria for the primary trial state that the trial is for women with metastatic breast cancer who are post-menopausal or pre-menopausal. The criteria do not include any mention of children. Therefore, it is not the case that adults and children can take part in the primary trial."}
{"id": "6b35bc10-f591-4b84-abac-40a74be949fa", "result": "Entailment.\n\nThe statement \"Prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is not admissible for the primary trial\" is entailed by the given information. The eligibility criteria for the primary trial state that patients who have prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor are not eligible for the trial. Therefore, it is not the case that prior treatment with fulvestrant or with a phosphatidylinositol 3-kinase (PI3K) inhibitor is admissible for the primary trial."}
{"id": "a5baab2c-9c32-4301-a574-4ba5a0c2eb00", "result": "Contradiction.\n\nThe statement \"Presence of hot flashes for at least 4 month prior to study registration is required for all patients that want to participate in the primary trial or the secondary trial\" is not entailed by the given information. The eligibility criteria for the primary trial state that patients must have been experiencing hot flashes for 30 days prior to study registration, while the eligibility criteria for the secondary trial do not specify any duration of hot flashes prior to study registration. Therefore, it is not the case that all patients must have hot flashes for at least 4 months prior to study registration in order to participate in the primary or secondary trial."}
{"id": "70677d5f-7022-404c-8410-d1f89366d92f", "result": "Contradiction.\n\nThe statement \"the secondary trial and the primary trial both measure the pCR and tumor diameter of their patient cohorts\" is not entailed by the given information. The primary trial results measure the pathologic complete response rate (pCR) as defined by the absence of residual invasive cancer in both the breast and axillary lymph nodes. The secondary trial results, on the other hand, do not provide a pCR for either arm, but rather measure disease-free survival, which is defined as the percentage of patients who are disease-free at 8 years. Therefore, it is not the case that both trials measure the pCR and tumor diameter of their patient cohorts."}
{"id": "f46a7d27-a94f-4389-a1a0-4a8f5177b354", "result": "Contradiction.\n\nThe statement \"None of the individual Aes recorded in the primary trial affect more than than one patient\" is not entailed by the given information. The adverse events section of the primary trial states that the total number of patients who experienced anaemia in Adverse Events 1 was 4/100 (4.00%), while the total number of patients who experienced anaemia in Adverse Events 2 was 0/152 (0.00%). Therefore, it is not the case that none of the individual Aes recorded in the primary trial affect more than than one patient."}
{"id": "fe876bb0-7ce3-4197-81ad-920f1f77938e", "result": "Contradiction.\n\nThe statement \"there is a minimal difference between the results from the two the primary trial cohorts\" is not entailed by the given information. The results from the primary trial show that the percentage of participants in the exemestane arm who were event-free at 5 years was 88 (87 to 89), while the percentage of participants in the anastrozole arm who were event-free at 5 years was 89 (88 to 90). This represents a difference of 1 percentage point, which is not minimal. Therefore, it is not the case that there is a minimal difference between the results from the two primary trial cohorts."}
{"id": "f45ff82d-e0f5-456a-9d78-ddc2dc6ab929", "result": "Contradiction.\n\nThe statement \"to be eligible for the primary trial candidates must be over the age of 18, have a severe disability and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels\" is not entailed by the given information. The eligibility criteria for the primary trial do not require that candidates have a severe disability or adequate hepatic, renal and heart functions. Therefore, it is not the case that candidates for the primary trial must be over the age of 18, have a severe disability and adequate hepatic, renal and heart functions as well as adequate hematology levels to be eligible for the primary trial."}
{"id": "4f705481-5dd0-414c-b375-c56e8c235b42", "result": "Contradiction.\n\nThe statement \"The most common adverse event in the primary trial was skin infection\" is not entailed by the given information. The most common adverse event in the primary trial was anemia, with a frequency of 1/41 (2.44%). The total number of participants who experienced skin infection was 2/41 (4.88%). Therefore, it is not the case that the most common adverse event in the primary trial was skin infection."}
{"id": "614d7ade-0fa7-4d77-bc19-1d3a2f2f48c2", "result": "Contradiction.\n\nThe statement \"Febrile Neutropenia was the most common adverse event recorded in the primary trial, affecting most patients in the trial\" is not entailed by the given information. The most common adverse event in the primary trial was febrile neutropenia, which affected 3/56 (5.36%) of patients. However, this is not most of the patients in the trial, and so it is not the case that febrile neutropenia was the most common adverse event recorded in the primary trial and affected most patients in the trial."}
{"id": "c09fa61c-967a-40ae-96b0-c87b7cde237b", "result": "Entailment.\n\nThe statement \"None of the individual Aes recorded in the primary trial affect more than 10% of the population\" is entailed by the given information. In Adverse Events 1, the most common adverse event was anemia, which affected 4/100 (4.00%) of the population. In Adverse Events 2, the most common adverse event was febrile neutropenia, which affected 3/152 (1.97%) of the population. Neither of these values exceed 10%, and so it is true that none of the individual Aes recorded in the primary trial affect more than 10% of the population."}
{"id": "4309860d-042d-45a4-8a0a-a9fdd075247a", "result": "Contradiction.\n\nThe statement \"Cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion\" is not entailed by the given information. In Intervention 1, it is stated that NKTR-102 will be administered at a dose level of 145 mg/m2 on a q21d schedule as a 90-minute intravenous (IV) infusion on Day 1 of each treatment cycle in Group A. Therefore, it is not the case that cohort 1 and 2 of the primary trial do not receive NKTR-102 by infusion."}
{"id": "f2275929-7cfe-4bb1-a9f6-6bd0c4d5bf85", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial use identical outcome measurements\" is not entailed by the given information. The primary trial measures overall response (CR, PR or SD) of participants, while the secondary trial measures percentage of participants with pathological complete response (pCR) in breast and axilla as defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System. These are not identical outcome measurements."}
{"id": "59cd7909-00c3-4c23-9a08-a42dbc8eabdd", "result": "Entailment.\n\nThe statement \"Participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression\" is entailed by the given information. The intervention in Intervention 1 is described as being administered until disease progression, with no specific number of cycles or time frame given. Therefore, it is true that participants of the primary trial will not receive the intervention for a set number of cycles, the cycles will continue until disease progression."}
{"id": "e6a4e9a6-56b8-4a30-9743-eb02688c090f", "result": "Entailment.\n\nThe statement \"A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm\" is entailed by the given information. The inclusion criteria for the primary trial states that subjects must have had complete resection (R0) of the primary tumor and axillary lymph nodes (or must have negative sentinel node[s]). The exclusion criteria do not mention node positive or node negative status as a disqualifying factor. Therefore, it is true that a patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of 1.5cm."}
{"id": "82a3e542-f784-44d7-90f6-34d7e969283c", "result": "Entailment.\n\nThe statement \"the primary trial participants receive more than one type of medication during the study\" is entailed by the given information. In Intervention 1, it is stated that all patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking. This implies that participants in the primary trial are receiving more than one type of medication during the study, namely Avastin (Bevacizumab) and hormonal therapy."}
{"id": "fb360514-14be-45ab-8b74-ea5a7eb181d7", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial do not report adverse events\" is not entailed by the given information. In Adverse Events 1 of the primary trial, the total number of participants who experienced an adverse event was 0/23 (0.00%). In Adverse Events 1 and 2 of the secondary trial, the total number of participants who experienced an adverse event was 0/655 (0.00%) and 0/580 (0.00%), respectively. Therefore, it is not true that the primary trial and the secondary trial do not report adverse events."}
{"id": "7137dec6-5c98-4156-8035-7bbaaf0b649d", "result": "Contradiction.\n\nThe statement \"ECOG score < 2 is necessary to be eligible for the primary trial\" is not entailed by the given information. The inclusion criteria for the primary trial state that the Eastern Cooperative Oncology Group (ECOG)-performance status of 0-1 is required. The exclusion criteria do not mention ECOG score < 2 as a disqualifying factor. Therefore, it is not true that ECOG score < 2 is necessary to be eligible for the primary trial."}
{"id": "015dd869-db90-45a9-a951-9dc7dc2b2e01", "result": "Contradiction.\n\nThe statement \"patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial\" is not entailed by the given information. The inclusion criteria for the primary trial state that the patient must not have cancer that has spread to the brain. Additionally, the exclusion criteria state that treatment with Gemcitabine or Pemetrexed is not allowed, which would exclude patients with colon cancer, as these are common treatment options for that disease. Therefore, it is not true that patients with a Malignant brain tumour or colon cancer diagnosis are eligible for the primary trial."}
{"id": "3a4003f6-ff1c-43d8-be48-f767266b2cf5", "result": "Contradiction.\n\nThe statement \"the secondary trial and the primary trial do not have the same inclusion and exclusion conditions\" is not entailed by the given information. Both the primary and secondary trial eligibility sections state that the trial requires \"Female or male patients with diagnosis of invasive adenocarcinoma of the breast confirmed at MSKCC\" and that the trial requires \"ECOG performance status of 0 or 1\" and \"Age > or = to 18 years old.\" Additionally, both trials require that the patient have evidence of recurrent or progressive locally advanced or metastatic breast cancer and that the patient have a paraffin-embedded tissue block or unstained slides from prior surgery available. Therefore, it is not true that the secondary trial and the primary trial do not have the same inclusion and exclusion conditions."}
{"id": "47ba01d6-edc7-4acb-ab49-b0e86f4eeaf7", "result": "Contradiction.\n\nThe statement \"at least 2 participants of the primary trial, at least one from each cohort, had a Progression-Free Survival of 10.8 months\" is not entailed by the given information. The results section of the primary trial states that the median progression-free survival was 9.1 months in the Paclitaxel/Bevacizumab/Everolimus arm and 7.1 months in the Paclitaxel/Bevacizumab/Placebo arm. The term \"median\" refers to the middle value, and it indicates that more than half of the participants had a progression-free survival of less than 9.1 months in the Paclitaxel/Bevacizumab/Everolimus arm and less than 7.1 months in the Paclitaxel/Bevacizumab/Placebo arm. Therefore, it is not true that at least two participants in the trial had a progression-free survival of 10.8 months."}
{"id": "f3cb9150-32c6-4877-9a87-4fac45a24948", "result": "Contradiction.\n\nThe statement \"Between the secondary trial and the primary trial, all the recorded cases of Musculoskeletal adverse events occurred in cohort 2 of the secondary trial\" is not entailed by the given information. The primary trial did not record any cases of musculoskeletal adverse events, while the secondary trial recorded one case of musculoskeletal adverse events in cohort 1 and one case in cohort 2. Therefore, it is not true that all recorded cases of musculoskeletal adverse events occurred in cohort 2 of the secondary trial."}
{"id": "9d8b26d6-d574-4717-88b6-77458bc683f3", "result": "Contradiction.\n\nThe statement \"Syncope was the most common adverse event recorded in the primary trial\" is not entailed by the given information. The primary trial recorded one case of dyspnea (1.82%) but no cases of syncope. Therefore, it is not true that syncope was the most common adverse event recorded in the primary trial."}
{"id": "51be7c95-8da4-419c-950c-91ebdd2c3fe5", "result": "Contradiction.\n\nThe statement \"All patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial\" is not entailed by the given information. The primary trial intervention includes BKM120 and paclitaxel, while the secondary trial intervention includes an active breathing coordinator (ABC) device, which is used to compare dose distributions from free-breathing versus ABC plans. However, the given information does not indicate the doses of BKM120 that are administered to patients in either trial. Therefore, it is not possible to determine whether all patients in the primary trial receive higher doses of BKM120 than patients in the secondary trial."}
{"id": "07042b0f-d422-49c3-8d53-81319927a4b3", "result": "The statement \"all participants of the primary trial have stage 2 or 3 histologically or cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial\" is not entailed by the given information. The primary trial eligibility section states that patients must have preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging. On the other hand, the secondary trial eligibility section states that patients with metastatic or advanced solid tumors are eligible. Therefore, the specific stage of cancer required for entry into the secondary trial may be different from that required for entry into the primary trial."}
{"id": "32361e21-ee57-4c34-9390-833ba5048a10", "result": "The statement \"the primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally\" is not contradicted by the given information. The intervention section of the primary trial states that Fulvestrant is administered intramuscularly in a loading dose schedule and that Everolimus is administered orally. However, the information does not specify the injection site for Fulvestrant. The deltoid is a common site for intramuscular injections, but other sites, such as the gluteus maximus, are also used. Therefore, it is not possible to determine from the given information whether primary trial participants are administered Fulvestrant intramuscularly (to the deltoid) and Everolimus orally."}
{"id": "88668508-dfd4-4a39-91cd-cf1654a6dfc4", "result": "Contradiction.\n\nThe statement \"the primary trial does not report the PFS or objective response rate of its patient cohort, instead reporting the proportion of patients which experience dermatitis\" is not entailed by the given information. The primary trial results section states that the outcome measurement is local control using ipsilateral breast tumor recurrence rates. The result reported is 70.9% of patients experiencing dermatitis. Therefore, it is not true that the primary trial does not report the PFS or objective response rate."}
{"id": "dca4c9f7-bb2a-4f73-b390-93b7ced87c73", "result": "The statement \"The results from the secondary trial and the primary trial are non-comparable\" is not entailed by the given information. Both trials have the same outcome measurement: change in Masood score. The primary trial reports the results for patients receiving Trastuzumab and Abraxane followed by Trastuzumab and Vinorelbine, while the secondary trial reports the results for patients receiving placebo or Arzoxifene. However, the given information does not indicate whether the two trials are comparable in terms of the distribution of baseline Masood scores or other patient characteristics that may affect the change in Masood score. Therefore, it is not possible to determine whether the results from the secondary trial and the primary trial are comparable based on the provided information."}
{"id": "e7604382-09cd-43b4-998f-a51b33f25c5a", "result": "The statement \"the primary trial and the secondary trial participants do not receive any medication orally\" is not entailed by the given information. The primary trial intervention includes intraductal administration of dextrose or dextrose with PLD prior to conventional surgery for breast cancer. The secondary trial intervention includes cetuximab, which is given intravenously. Therefore, it is possible that some participants in the primary trial and the secondary trial receive medication orally. However, the given information does not provide enough details to determine whether this is the case."}
{"id": "75affd49-4905-4d43-9a5c-ef795281bac4", "result": "The statement \"neither of the interventions in the primary trial resulted in an Objective Benefit for more than 40% of patients\" is entailed by the given information. According to the results, the overall response rate for Arm A is 28 (16 to 42) and for Arm B is 31 (18 to 45). Therefore, neither of the interventions resulted in an objective benefit for more than 40% of patients, as both are less than 40%."}
{"id": "2e76c74a-b6dd-47d8-a674-c1e80b0a3a65", "result": "The statement \"to be eligible for the primary trial patients must be diagnosed with hormone receptor positive advanced breast cancer, and have received prior chemotherapy for this cancer\" is not entailed by the given information. The inclusion criteria only states that patients must have confirmed hormone receptor positive advanced breast cancer, postmenopausal women. It does not specify that they must have received prior chemotherapy."}
{"id": "8c6314f7-34f5-42a7-ba66-b95d050a6315", "result": "The statement \"The shortest PFS in cohort 1 of the primary trial was 1.4 months below average\" cannot be inferred from the given trial information. The results show that the median PFS for Arm/Group Title: NK105 was 8.4 (7.0 to 9.9) and for Arm/Group Title: Paclitaxel was 8.5 (6.9 to 11.5). Neither of these results indicate that the shortest PFS was 1.4 months below average."}
{"id": "f114846e-79d8-4712-add0-bb34b65d418f", "result": "The statement \"there were 6 recorded deaths in cohort 1 of the primary trial and 7 in cohort 2\" is not entailed by the given information. The results indicate that there were 6 patients event-free in cohort 1 and 7 patients event-free in cohort 2, but it does not indicate the number of recorded deaths in each cohort. In fact, the results indicate that all patients in cohort 1 had an event, whereas only 7 out of 7 patients in cohort 2 had an event. Without knowing the total number of patients in each cohort, it is not possible to determine the number of recorded deaths in each cohort."}
{"id": "812bd63c-4bfb-49cb-8fa9-baa3f8f6dabe", "result": "The statement \"the primary trial reports the changes in the number of lesions for patients in its cohorts\" is not entailed by the given information. The results reported are changes in tumor size (CTS) from baseline to the end of Cycle 2. The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant. The results do not provide information about the number of lesions."}
{"id": "b1d28450-fc7d-496a-9c7c-bf711b28f8e4", "result": "The statement is a contradiction. The eligibility criteria state that pregnant patients are excluded from the trial, so it does not make sense to say that all pregnant patients accepted into the trial have undergone prior treatment for breast cancer with endocrine therapy."}
{"id": "c7dc582a-4a58-4cb5-b980-b2d2b6a128c3", "result": "The statement \"no cardiac or neural adverse events were recorded in the primary trial\" cannot be inferred from the given information, since the only adverse events reported are dry eyes and diarrhea. There is no mention of cardiac or neural adverse events. Therefore, the statement contradicts the information in the Adverse Events section."}
{"id": "a805f174-2707-4302-a195-05153ea8523e", "result": "The statement \"Only adults can take part in the primary trial\" cannot be inferred from the given information. The eligibility criteria do not mention anything about age restrictions."}
{"id": "e4aeb013-7713-4b73-acbd-f8379cc6a494", "result": "The statement \"there was a higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1\" is entailed by the given information. The results indicate that there were 0/101 (0.00%) patients with slipped disks in cohort 1 and 1/98 (1.02%) in cohort 2, which supports the statement."}
{"id": "b8eaa8fd-61cf-4ca9-aaec-267d61c1fae3", "result": "The statement \"All patients in cohort 1 of the primary trial had a PFS of over 7 months, with the highest PFS being just under 10 months\" is not entailed by the given information. The results indicate that the mean PFS for Arm/Group Title: Neratinib Plus Capecitabine was 8.8 (7.8 to 9.8) months, which means that some patients had a PFS of less than 7 months. Therefore, the statement is not supported by the results."}
{"id": "2729a321-709b-4392-9604-dd7237bedb17", "result": "The statement \"the majority of participants in cohort 1 and 2 of the primary trial achieved Disease-free Survival for 5 years\" is not supported by the given information. In fact, the results suggest that the majority of participants did not achieve Disease-free Survival for 5 years, as the percentage of patients is only 80.1% for cohort 1 and 82.2% for cohort 2. It is possible that some patients in these cohorts did achieve Disease-free Survival for 5 years, but the results do not indicate that the majority did."}
{"id": "8e9611fc-89f8-44cb-af09-8d71a13ca082", "result": "The statement \"Cohort 1 and 2 of the primary trial do not receive the same intervention\" can be inferred from the provided information. The interventions for Cohort 1 are NKTR-102 and TPC, while the intervention for Cohort 2 is TPC only. Therefore, it is certain that Cohort 1 and 2 do not receive the same intervention."}
{"id": "b9491012-49ba-4eb1-8230-1966f54ea012", "result": "The statement \"Patients with Extracranial metastases can be eligible for the primary trial\" is not explicitly stated in the eligibility section provided, but it can be inferred. The eligibility section does not exclude patients with extracranial metastases; therefore, they can be eligible."}
{"id": "62e449ad-16b3-479d-94a5-ffc435b5e99c", "result": "The statement \"patients with a Malignant brain tumour diagnosis are excluded from the primary trial\" is entailed by the given eligibility criteria. The exclusion criteria state that patients with cancer that has spread to the brain are excluded from the trial. Therefore, it can be inferred that patients with a malignant brain tumour diagnosis are excluded from the trial."}
{"id": "565d7982-aa9a-4c01-987c-1d67bc9c212d", "result": "The statement \"ongoing flucytosine treatments are necessary for all participants of the primary trial, treatments must have started at least 6 months before study entry\" cannot be inferred from the given eligibility criteria. The eligibility criteria only state that patients cannot be treated with flucytosine. There is no mention of the duration of flucytosine treatment before study entry."}
{"id": "7271e0db-bb82-423f-ad95-5ffa84fab97e", "result": "Entailment:\nThe statement \"There are more cases of Urosepsis in the primary trial than in the secondary trial\" is entailed by the given trial information. The primary trial has 25.00% (3/12) incidence of Urosepsis, while the secondary trial has 0.00% (0/65) incidence of Urosepsis. Therefore, the primary trial has more cases of Urosepsis than the secondary trial."}
{"id": "6402e13a-7cfb-4774-b7f9-80ecb79fda2a", "result": "The statement \"the primary trial participants are not administered any oral medication whereas the secondary trial patients only receive treatment orally\" contradicts the given trial information. The primary trial intervention includes ultrasound guided biopsy of axillary lymph node if suspicious, which requires the patient to take an oral medication. Additionally, the secondary trial interventions both include oral medication. Intervention 1 includes exemestane, and Intervention 2 includes anastrozole, both given orally."}
{"id": "734423d5-4b47-4448-ab98-811015d626f0", "result": "Contradiction:\nThe statement \"There were multiple patients which suffered Neutropenia in both cohorts of the primary trial\" is contradicted by the given trial information. The primary trial Adverse Events 1 shows that 1/39 (2.56%) patients in cohort 1 suffered Neutropenia, while the primary trial Adverse Events 2 shows that 1/21 (4.76%) patients in cohort 2 suffered Neutropenia. However, neither cohort had multiple patients who suffered Neutropenia. Therefore, the statement is contradicted by the trial information."}
{"id": "e9fd065c-342c-4dfb-9c1c-a4c0c44d0acd", "result": "Entailment:\nThe statement \"All the primary trial participants are administered Anastrazole in a pill form, but none of the secondary trial receive any Anastrazole\" is entailed by the given trial information. The primary trial Intervention 1 shows that both Arm A and Arm B receive anastrazole in a pill form, while the secondary trial Intervention 1 shows that none of the secondary trial participants receive anastrazole. Therefore, the statement is entailed by the trial information."}
{"id": "32ed503c-1cfd-44f6-b8bb-23d9d175d73d", "result": "Entailment:\nThe statement \"Patients must be able to undergo a PET scan to participate in the primary trial\" is entailed by the given trial information. The eligibility criteria include the requirement that patients must be able to lie still for 1.5 hours for PET scanning. This requirement implies that patients must be able to undergo a PET scan, and thus, the statement is entailed by the trial information."}
{"id": "175044aa-72b1-405d-8506-30002f5098e4", "result": "Contradiction:\nThe statement \"There adverse events section in the primary trial describes the number of patients that suffered Hypotension, Hemorrhage and Bradycardia when taking part in the study\" contradicts the given trial information. The primary trial Adverse Events 1 does not mention the number of patients that suffered Hypotension, Hemorrhage, and Bradycardia. Therefore, the statement is contradicted by the trial information."}
{"id": "045ad91e-44fa-42cc-ac22-a7aab26a9009", "result": "Contradiction:\nThe statement \"the primary trial participants are administered Avastin, Bevacizumab and radiotherapy as part of the intervention\" contradicts the given trial information. The primary trial intervention only mentions that patients received Avastin (Bevacizumab) 15 mg/kg IV every three weeks as well as continuing with hormonal therapy they previously were taking. There is no mention of radiotherapy as part of the intervention."}
{"id": "00822101-fa21-4a26-bf45-3b1f535da005", "result": "Contradiction:\nThe statement \"a patient with a HER2-positive status can not take part in the primary trial\" contradicts the given trial information. The primary trial eligibility includes patients with HER2-positive status. The exclusion criteria only exclude patients with unknown HER2 status and patients who have received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) pathway-targeted therapy."}
{"id": "06f798d1-2956-4903-83e9-58a41fa425f7", "result": "Contradiction:\nThe statement \"the primary trial and the secondary trial do not record any cardiac or infection related adverse events\" contradicts the given trial information. The primary trial Adverse Events 1 reports that 3/655 (0.46%) patients suffered from neutropenia, which is a cardiac adverse event. The secondary trial Adverse Events 1 reports that 1/15 (6.67%) patients suffered from neutropenia, which is also a cardiac adverse event. Therefore, the statement is contradicted by the trial information."}
{"id": "8648c7df-582a-42a9-9330-414b2430ac56", "result": "Contradiction:\nThe statement \"none of the individual adverse events in the primary trial affect more than 100 patients, in total less than 30 patients suffer adverse events\" is contradicted by the given trial information. The primary trial Adverse Events 1 shows that 7/1612 (0.43%) patients suffered from febrile neutropenia, which affects more than 100 patients. Also, in total, more than 30 patients suffered adverse events in the primary trial Adverse Events 1. Therefore, the statement is contradicted by the trial information."}
{"id": "89f610a7-9e81-43a4-8c1e-5503233b2be1", "result": "Entailment:\nThe statement \"Breast cancer patients must have documented stable disease to participate in the primary trial\" is entailed by the given trial information. The eligibility criteria include patients with documented progressive disease. Therefore, breast cancer patients must have documented stable disease to participate in the primary trial."}
{"id": "b0046821-ba27-4a90-8869-cb708b843aa4", "result": "Entailment:\nThe statement \"All the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed\" is entailed by the given trial information. The primary trial intervention includes flaxseed in both arms, while the secondary trial intervention does not include flaxseed in either arm. Therefore, all the primary trial participants are administered flaxseed, but none of the secondary trial receive any flaxseed."}
{"id": "d1b217ae-76f3-4ba6-958e-5b2558703ba4", "result": "Contradiction:\nThe statement \"several cases of congestive heart failure in the primary trial occurred in cohort 1, but none in cohort 2\" is contradicted by the given trial information. The primary trial Adverse Events 1 shows that 1/35 (2.86%) patient suffered from congestive heart failure in cohort 1. However, the primary trial Adverse Events 2 shows that 0/40 (0.00%) patients suffered from congestive heart failure in cohort 2. Therefore, the statement is contradicted by the trial information."}
{"id": "8ddf8b88-6e06-4c71-9e28-45f73a637af0", "result": "Contradiction:\nThe statement \"the primary trial participants are administered oral and topical medication, whereas the secondary trial patients only receive treatment orally\" is contradicted by the given trial information. The primary trial intervention does not include any oral or topical medication, while the secondary trial intervention includes oral medication in both arms. Therefore, the statement is contradicted by the trial information."}
{"id": "0ea29bd5-20be-40ea-8ad7-705d283d1d48", "result": "Contradiction:\nThe statement \"the majority of participants in cohort 1 and 2 of the primary trial suffered some kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer\" is contradicted by the given trial information. The primary trial results 1 and 2 show that the percentage of patients alive and cancer-free in cohort 1 and 2 are 80.1 (78.0 to 82.0) and 82.2 (80.2 to 84.0) respectively, which means that the majority of participants in cohort 1 and 2 did not suffer any kind of disease Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer. Therefore, the statement is contradicted by the trial information."}
{"id": "e147796d-2edd-42d1-ac53-300fb8bd5eb6", "result": "Contradiction:\nThe statement \"80% of patients in the primary trial received a placebo intervention\" is contradicted by the given trial information. The primary trial intervention shows that only 50% of patients received a placebo, while the other 50% received lapatinib. Therefore, the statement is contradicted by the trial information."}
{"id": "6b33b4ae-36f2-4a53-a954-6f246f6e023d", "result": "Entailment:\nThe statement \"Patients wanting to take part in the primary trial must have a Known and documented HER2+ status and an LVEF of at least 50 percent (%)\" is entailed by the given trial information. The eligibility criteria of the primary trial include patients with known and documented HER2-positive disease and LVEF of at least 50 percent. Therefore, patients wanting to take part in the primary trial must have a known and documented HER2+ status and an LVEF of at least 50 percent."}
{"id": "06fad978-1dc3-46f5-b45f-5ac6577f28b9", "result": "Contradiction:\nThe statement \"Patients must be female and have confirmed advanced colon cancer to be eligible for the secondary trial and the primary trial\" is contradicted by the given trial information. The primary trial eligibility includes females with histologic or cytologic diagnosis of advanced breast cancer, while the secondary trial eligibility includes confirms hormone receptor positive advanced breast cancer, postmenopausal women. Therefore, the statement is contradicted by the trial information."}
{"id": "878c09e7-3fd9-404e-921e-5b549e9578fb", "result": "Contradiction:\nThe statement \"Most patients in the primary trial experienced a grade 1 adverse events, the least common severity was grade 4\" is contradicted by the given trial information. The primary trial results 1 shows that the percentage of patients with grade 1, 2, 3, 4, and 5 adverse events are 75.7 (53/70), 57.1 (40/70), 25.7 (18/70), 2.9 (2/70), 0 (0/70), and 17.1 (12/70) respectively. Therefore, the statement is contradicted by the trial information."}
{"id": "3a0c517d-9b9a-4497-9675-50ff12cd02b7", "result": "Contradiction:\nThe statement \"in cohort 1 of the primary trial there were more cases of Left ventricricular dysfunction than Abdominal pain\" is contradicted by the given trial information. The primary trial adverse events 1 shows that the percentage of patients with Left ventricular dysfunction and Abdominal pain are 0.91% (2/219) and 0.46% (1/219) respectively. Therefore, the statement is contradicted by the trial information."}
{"id": "9abb10d7-496e-44fd-915d-d86aedf6c9b6", "result": "Contradiction:\nThe statement \"Patients wanting to take part in the primary trial must have a Known and documented TNBC status and an LVEF of at least 50 percent (%)\" is contradicted by the given trial information. The primary trial eligibility includes patients with known and documented HER2-positive disease and LVEF of at least 50 percent, while it does not mention TNBC status. Therefore, the statement is contradicted by the trial information."}
{"id": "8460a212-8054-4bd2-b4e6-af1d137a2f79", "result": "Contradiction:\nThe statement \"the primary trial and the secondary trial report their results using different units of measure\" is contradicted by the given trial information. The primary trial results 1 and the secondary trial results 1 both use percentage of participants as the unit of measure. Therefore, the statement is contradicted by the trial information."}
{"id": "a3390ae6-d41d-4dc7-899e-de9534adfd6b", "result": "Entailment:\nThe statement \"the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib\" is entailed by the given trial information. The primary trial intervention states that participants took lapatinib and capecitabine. Capecitabine was orally administered at 1000 mg per square meter (mg/m^2) twice daily on the first day through the fourteenth day of each 21-day cycle. Lapatinib was orally administered at 1250 milligrams (mg) once daily. Therefore, the primary trial participants receive significantly higher doses of Capecitabine than of Lapatinib."}
{"id": "17bbea92-8f92-41f3-9b9d-cf6e62cf6798", "result": "Contradiction:\nThe statement \"the primary trial reports the percentage of patients treated with Neratinib in Combination With Paclitaxel that suffer side effects that are serious enough to prevent an increase in dose or level of that treatment\" is contradicted by the given trial information. The primary trial results 1 and 2 do not report the percentage of patients with side effects that are serious enough to prevent an increase in dose or level of Neratinib and Paclitaxel. Therefore, the statement is contradicted by the trial information."}
{"id": "794269ca-e7ec-4a65-ace5-b0f24a8cdc15", "result": "Entailment:\nThe statement \"the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS\" is entailed by the given trial information. The primary trial results 1 and 2 report the percentage of participants with objective response, while the secondary trial results 1 reports median PFS. Therefore, the primary trial measures the Percentage of Participants in its cohorts With Objective Response whereas the secondary trial measures PFS."}
{"id": "4dfff980-6a2b-4f01-9194-6ec831d6fed7", "result": "Contradiction:\nThe statement \"Infections were the most common adverse events recorded in the primary trial\" is contradicted by the given trial information. The primary trial adverse events 1 report the number of infections to be 2/55 (3.64%). The number of other adverse events reported is 3/55 (5.45%). Therefore, the statement is contradicted by the trial information."}
{"id": "dc4c57b0-8c75-494e-81b0-3528df85ebff", "result": "Contradiction:\nThe statement \"neither the secondary trial or the primary trial record the Overall Survival (OS) of Patients in their cohorts\" is contradicted by the given trial information. The primary trial results 1 and 2 both report the median months of overall survival of patients in the cohorts. The secondary trial Results 1 reports the median months of overall survival of patients who received NKTR-102. Therefore, the primary trial and the secondary trial both record the Overall Survival (OS) of Patients in their cohorts."}
{"id": "8d9f94e3-871b-4fb4-a522-0a73d9d0ec3c", "result": "The statement entails from the given trial information. In the primary trial, Objective Response (OR) is defined as a patient having a best overall response of either complete response (CR) or partial response (PR). In contrast, the secondary trial defines Objective Response (OR) as complete response (CR) and partial response (PR). Therefore, they do use the same outcome measurement but with different definitions of complete response (CR)."}
{"id": "251a20d8-2555-4929-9d01-c02311bdc93f", "result": "The statement contradicts the given trial information. In the primary trial, 35 out of 50 participants (or 70%) in Arm 1 (Fulvestrant and Dasatinib) suffered Disease Progression or Death, while 40 out of 49 participants (or 81.6%) in Arm 2 (Fulvestrant) suffered Disease Progression or Death. Therefore, a higher proportion of patients suffered Disease Progression or Death in cohort 2 (Arm 2) of the primary trial than in cohort 1 (Arm 1)."}
{"id": "dd2f3c3d-fa95-4fca-a3f0-795fd4f3abf1", "result": "The statement entails from the given trial information. The primary trial measures LDex Change, which is a bioimpedance measurement, while the secondary trial measures Overall Survival (OS) in months. Since the metrics used to measure outcomes are different in each trial, the statement is correct."}
{"id": "f0273b8c-460d-46fe-9c52-8ff4b08e439b", "result": "Contradiction.\n\nThe statement contradicts the given trial information because eligibility for the primary trial is not based on age. The inclusion criteria only require that participants be women aged 18 or older with newly diagnosed infiltrating (invasive) breast cancer, whether HER2-neu-negative or HER2-neu-positive. The exclusion criteria only rule out participants with evidence of metastatic disease, except for ipsilateral axillary lymph nodes, and those who have had previous systemic or local primary treatment.\n\nTherefore, eligibility for the primary trial is based on the type and stage of breast cancer, as well as previous treatment history, and not on age. Since eliane is a 56 year old woman, and elizabeth is a 32 year old woman, they both meet the age requirement, but we cannot determine if they meet the other eligibility criteria without more information."}
{"id": "bc2024fc-5b39-4fa6-badf-f034d6fe8bb8", "result": "Entailment.\n\nThe statement is entailed by the given trial information because one of the inclusion criteria for the primary trial is a \"pathologically confirmed diagnosis of breast cancer with documented progressive disease.\" Therefore, breast cancer patients with documented progressive disease are eligible for the primary trial."}
{"id": "c2217d42-e90c-4ffe-b084-e653b9ace4d5", "result": "Contradiction.\n\nBased on the given trial information, the primary and secondary trials do not record any instances of epilepsy as adverse events. Therefore, the statement is not entailed by the given trial information."}
{"id": "080da381-b5dd-46d3-99c4-18112da153c1", "result": "Contradiction.\n\nAccording to the primary trial Adverse Events section, there are no cases of acute myocardial infarction, cardiopulmonary failure, or supraventricular tachycardia in either cohort 1 or cohort 2.\n\nAccording to the secondary trial Adverse Events section, there are 0 cases of acute myocardial infarction, 1 case of cardiopulmonary failure, and 1 case of supraventricular tachycardia in cohort 1, and 1 case of acute myocardial infarction in cohort 2.\n\nTherefore, there are more cases of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia in cohort 2 of the primary trial than in cohort 1 of the secondary trial."}
{"id": "c100a7cd-e3a2-4901-a3e0-12336f769c7b", "result": "Contradiction.\n\nThe secondary trial reported 1 single case of conjunctivitis (0.19%), while the primary trial reported no cases of conjunctivitis. Therefore, the statement is a contradiction."}
{"id": "ec1e269e-470d-43d9-8f23-8a19a5c96fcc", "result": "The statement is a contradiction. The most common adverse event in Cohort 1 was anaemia, which occurred in 7/199 (3.52%) of patients. The most common adverse event in Cohort 2 was acute myocardial infarction, which occurred in 1/36 (2.78%) of patients. Tachycardia was not the most common adverse event in either cohort."}
{"id": "21611c2a-e6eb-4012-a209-9b6781e1f260", "result": "Contradiction.\n\nThe statement \"There is no adverse events section in the primary trial\" contradicts the given trial information since there is an Adverse Events section in the primary trial. The Adverse Events section in the primary trial reports adverse events that occurred in the trial, including the number of patients who experienced each event and the percentage of patients who experienced each event relative to the total number of patients in the trial."}
{"id": "d1b7105d-0b7d-4b10-92a7-d63243ff0629", "result": "Contradiction.\n\nThe primary trial exclusion criterion states that patients with a resting ejection fraction < 50% are ineligible. However, the secondary trial exclusion criterion states that patients with an ejection fraction < 50% are ineligible, except for premenopausal women 55 years of age or younger. Therefore, the statement that patients with significantly low ejection fraction are excluded from the primary trial, but can still be eligible for the secondary trial if they are 55 years of age or younger is a contradiction."}
{"id": "7f3fe97e-68ee-470f-b06e-21cdddb67aa8", "result": "Entailment\n\nThe primary trial eligibility requires patients to have completed preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging. The secondary trial eligibility does not require a specific stage of cancer for entry. Therefore, the statement that all participants of the primary trial have stage 3 cytologically confirmed invasive breast cancer, there is no specific stage of cancer required for entry to the secondary trial is an entailment."}
{"id": "ce8464bd-951e-44aa-97d9-10b917b055ce", "result": "Contradiction.\n\nAccording to the provided information, there were 0/101 (0.00%) patients with slipped disks in cohort 1 and 1/98 (1.02%) patients with slipped disks in cohort 2. Therefore, the statement that there was a significantly higher percentage of patients with slipped disks in cohort 2 of the primary trial than in cohort 1 is a contradiction."}
{"id": "0131ebe3-746b-45a5-ba60-fdd326974fec", "result": "Contradiction.\n\nThe primary trial outcome measurement is Overall Response (Complete Response [CR], Partial Response [PR] or Stable Disease [SD]) of participants, while the secondary trial outcome measurement is the percentage of participants with pathological Complete Response (pCR) in breast and axilla as defined by ypT0/Tis ypN0 in the American Joint Committee on Cancer (AJCC) Staging System. Therefore, the statement that the primary trial and the secondary trial use comparable outcome measurements is a contradiction.\n\nThe primary trial measures overall response, which is a composite of complete response, partial response, and stable disease, while the secondary trial measures pathologic complete response (pCR), which is the absence of residual invasive tumor in the breast and axilla after surgical resection. The primary trial outcome is measured at 6 months, while the secondary trial outcome is measured at the surgery visit (at approximately Weeks 14 to 19)."}
{"id": "b1dd7632-ed92-40a9-9293-bce68619c658", "result": "Entailment.\n\nThe primary trial eligibility includes patients with newly diagnosed stage I-III cancer of the female breast, and the statement that patients with stage 4 cancer are excluded from the primary trial, only patients with stage 2 and 3 cancer can be eligible is an entailment, as stage 4 cancer is not included in stage I-III."}
{"id": "45ccd2c8-6e02-4f0f-a370-eed18d26e6dc", "result": "Entailment.\n\nThe intervention for the primary trial includes Fulvestrant + Everolimus, and Fulvestrant is administered intramuscularly and Everolimus is administered orally, so the statement that primary trial participants are administered Fulvestrant intramuscularly and Everolimus orally is entailed by the given information."}
{"id": "4a15ec5e-4904-4f01-a0a2-c51e83c8c070", "result": "Entailment.\n\nThe primary trial's outcome measurement is severity of dermatitis in radiation treatment site in breast cancer patients, and the results include arms for Curcumin C3 Complex and Placebo, which suggests that the reported results are for these two arms. Therefore, the statement that the primary trial reports the severity of dermatitis in radiation treatment site for the Curcumin C3 Complex cohort and the placebo cohort is entailed by the given information."}
{"id": "b9e29ea8-6847-40d4-b5c3-81c496101695", "result": "Contradiction.\n\nThe statement that all patients in cohort 1 of the primary trial had a PFS of over 8.8 months, with the highest PFS being just under 10 months is a contradiction, since the results reported for Arm/Group Title: Neratinib Plus Capecitabine shows that the mean PFS was 8.8 months (7.8 to 9.8)."}
{"id": "2a2c16a7-f427-4fdb-8153-94aac304e4b8", "result": "Contradiction.\n\nThe statement that both cohorts of the primary trial undergo a total of 17 cycles, each lasting 3 weeks, patients receive the same types and dosages of medication throughout all 17 cycles is a contradiction, because the cohorts receive different medications and dosages, as shown in the interventions. Cohort 1 receives HER2+ TC (trastuzumab, doxorubicin, and paclitaxel) and cohort 2 receives HER2+ C (doxorubicin and paclitaxel). The duration and dosages of the medications are also different between the two cohorts."}
{"id": "618a3ae1-b22c-4c35-86a6-190c1b5b5d21", "result": "Entailment.\n\nThe statement \"Patients must have a Life expectancy of at least 1 year to enroll in the primary trial\" is entailed by the given information because \"Life expectancy 1 year\" is listed as an inclusion criterion for the primary trial."}
{"id": "e62f5a3f-0091-4980-9822-db8f4dc2502a", "result": "Contradiction.\n\nThe statement \"there is no difference in the results from these two cohorts\" is not supported by the results presented in the trial. The mean RDS score in the Curcumin C3 Complex cohort is 2.6 (0.994) and in the placebo cohort is 3.4 (0.554). The difference in means is 0.8, which is statistically significant based on a standard deviation of approximately 0.6. Therefore, the statement cannot be inferred from the given trial information."}
{"id": "4a41ac73-538a-43e5-b7ce-8c8e2d56286e", "result": "The given statement is entailed by the primary trial eligibility criteria but not the secondary trial eligibility criteria. The primary trial eligibility criteria exclude women who are currently undergoing endocrine therapy unless it is adjuvant therapy. However, the secondary trial eligibility criteria does not mention the relationship of endocrine therapy to the primary tumor. It only mentions that paraffin-embedded tissue must be available from metastatic sites, if reasonably accessible, or from the primary tumor."}
{"id": "75a65913-5655-4377-b441-ecdd4dd75175", "result": "The statement \"Patients with stage 4 cancer are excluded from the primary trial\" is entailed by the given trial information because the eligibility criteria for the primary trial explicitly state that the trial enrolls patients with newly diagnosed stage I-III cancer of the female breast. The trial does not enroll patients with stage 4 cancer. Therefore, patients with stage 4 cancer are excluded from the primary trial."}
{"id": "1329dec6-fb2c-4219-9db6-3fef9d94b316", "result": "Contradiction.\n\nThe statement \"in cohort 1 of the primary trial there were 10 more cases of Left ventricular dysfunction than Abdominal pain\" is not supported by the data.\n\nAdverse events in cohort 1 of the primary trial include 2 cases of left ventricular dysfunction and 1 case of abdominal pain.\n\nTherefore, there were not 10 more cases of left ventricular dysfunction than abdominal pain."}
{"id": "29b2fa29-5a76-4877-95bb-1a8de7973d33", "result": "The statement \"Only 6/67 patients in cohort 1 of the primary trial suffered adverse events\" is entailed by the given trial information. The Adverse Events section for the primary trial only lists six adverse events in cohort 1, so it can be inferred that only six patients suffered adverse events."}
{"id": "7edba90d-076d-4f55-b9d6-a1765ceb48bd", "result": "Contradiction.\n\nThe statement \"the primary trial and the secondary trial participants do not receive any medication by IV\" is not entailed by the given trial information.\n\nIn the primary trial, participants receive intraductal administration of dextrose or dextrose with pegylated liposomal doxorubicin hydrochloride (or PLD) prior to conventional surgery for breast cancer. In the secondary trial, patients receive cetuximab IV over 60-120 minutes once a week. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients not responding to treatment may cross over to arm II."}
{"id": "ba9daeb9-796d-49ab-a30c-4d8acbdf4d37", "result": "The statement \"in the primary trial, patients that received Fulvestrant were much more likely to suffer Disease Progression or Death than patients receiving herceptin\" is a contradiction. The primary trial did not include participants receiving herceptin as a treatment arm. The trial compared the efficacy of fulvestrant and dasatinib to fulvestrant alone. Therefore, it cannot be concluded that patients receiving fulvestrant were more likely to suffer disease progression or death than patients receiving herceptin."}
{"id": "1314146f-2869-4525-8034-7f732d238385", "result": "The statement \"none of the individual adverse events in the primary trial affect more than 100 patients\" is entailed by the given trial information. The Adverse Events sections for the primary trial list the total number of participants affected by each individual adverse event. In both Adverse Events 1 and Adverse Events 2, no individual adverse event affected more than 100 patients."}
{"id": "7c7418d2-32d7-4517-874b-eb3db24ea16a", "result": "The statement \"to be eligible for the primary trial candidates must be over the age of 18, have a Karnofsky score over 80 and Adequate hepatic, renal and heart functions aswell as Adequate hematology levels\" is entailed by the given trial information. The inclusion criteria for the primary trial state that candidates must be between 18 years and 70 years, have a Karnofsky performance status index > 80 %, and have adequate hepatic, renal, and heart functions, as well as adequate hematology levels. Therefore, candidates must meet these criteria to be eligible for the trial."}
{"id": "1f6a14ae-e22b-4b40-b389-217570dbf38e", "result": "The statement \"50% of cohort 2 patients in the primary trial suffered Dose Limiting Toxicities\" is a contradiction. According to the Results section of the primary trial, there was only 1 Dose Limiting Toxicity in cohort 2, which included 2 patients in total. Therefore, it cannot be concluded that 50% of cohort 2 patients suffered Dose Limiting Toxicities."}
{"id": "5c1e360c-fd93-4dd4-b855-71ba416d34cb", "result": "The statement \"patients must be able to receive medication orally to participate in the primary trial\" is entailed by the given trial information. The eligibility criteria for the primary trial include the ability to swallow an oral medication as an inclusion criterion and the absence of conditions that would affect the absorption of an oral drug as an exclusion criterion."}
{"id": "c7a953b0-ac96-4e0a-9c1d-98cf8af2861d", "result": "The statement \"the primary trial and the secondary trial report the same types of adverse events\" is a contradiction. The primary trial and the secondary trial report different types of adverse events. The primary trial reports adverse events related to AZD8931 in combination with weekly paclitaxel, while the secondary trial reports adverse events related to cetuximab and carboplatin after cetuximab alone. The adverse events listed in the primary trial include anemia, blood and lymphatic system disorders, febrile neutropenia, cardiac disorders, conduction disorder, myocardial infarction, palpitations, pericardial effusion, sinus bradycardia, while the secondary trial reports adverse events including anemia, blood and lymphatic system disorders, febrile neutropenia, cardiac disorders, myocardial infarction, pericardial effusion, and sinus bradycardia."}
{"id": "48f516ff-abb4-4312-9b00-02f53fb16218", "result": "The statement \"under a quater of the primary trial patients in the intervention arm experienced Pathologic Complete Response\" is entailed by the given trial information. The Results section states that the percentage of participants who experienced a pathologic complete response was 26%. Therefore, it can be inferred that less than a quarter of the primary trial patients in the intervention arm experienced Pathologic Complete Response."}
{"id": "978d19fc-e7f6-485e-b8bd-cfcde06441ab", "result": "The statement \"T1 N0 M0 patients are eligible for the primary trial\" is entailed by the given trial information. The eligibility criteria for the primary trial state that patients with histologically confirmed stage I, II, or III breast cancer are eligible, as long as they meet certain disease characteristics and patient characteristics. T1 N0 M0 patients meet these criteria, so they are eligible for the primary trial."}
{"id": "0a6d1b4c-244e-44e2-a229-62e4cbdfa979", "result": "The statement \"the results of the secondary trial and the primary trial are non-comparable\" is entailed by the given trial information. The primary trial reports the safety of external-beam PBI in selected stages 0 and I female breast cancer patients utilizing 40 Gy in ten daily fractions over two weeks, while the secondary trial reports the overall tumor response in participants receiving pemetrexed. The primary trial reports the number of participants who experienced specific toxicities, while the secondary trial reports the number of participants who experienced complete response, partial response, stable disease, progressive disease, and best response not evaluable. The primary and secondary trials are measuring different outcomes, so their results are not comparable."}
{"id": "9bcc31df-c1f6-4785-9235-f673213acf3a", "result": "The statement \"both the primary trial cohorts receive identical doses of Docetaxel\" is entailed by the given trial information. The Intervention section of the primary trial states that participants in both cohorts received docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). Therefore, it can be inferred that both the primary trial cohorts receive identical doses of Docetaxel."}
{"id": "63a0a9fc-80b9-450f-b2c6-7aee37ce26a9", "result": "The statement \"neither of the cohorts in the primary trial are required to undergo surgery or receive any oral medication as part of the intervention\" is entailed by the given trial information. The Intervention section of the primary trial does not mention any requirement for surgery or oral medication for either cohort. The first cohort receives no exercise, a multivitamin arm, and a calcitriol arm, while the second cohort receives exercise, a calcitriol arm, and a calcitriol+ exercise arm. Therefore, it can be inferred that the primary trial interventions do not require surgery or oral medication."}
{"id": "75cf4ec2-9f2b-4d5b-8772-af247eaca07b", "result": "The statement \"Patients with Histologically confirmed breast cancer stage I-III are not eligible for the primary trial\" is a contradiction to the given trial information. The eligibility criteria for the primary trial specify that patients with metastatic (stage IV) disease are eligible, and patients with stage I-III disease are explicitly included. Therefore, patients with stage I-III disease are eligible for the primary trial."}
{"id": "553f00ea-5197-4233-b1e0-e5727856b599", "result": "The statement \"no cardiac or bowel-related adverse events were recorded in the primary trial\" is a contradiction to the given trial information. The Adverse Events section of the primary trial lists dry eyes and diarrhea as adverse events, which are both potential bowel-related adverse events. Therefore, it can be inferred that cardiac or bowel-related adverse events were recorded in the primary trial."}
{"id": "57b2ae97-0d1d-4d5d-bc4b-109e8e5acb32", "result": "The statement \"There were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS and Anemia in the secondary trial than in the primary trial\" is entailed by the given trial information.\n\nThe primary trial has no reported adverse events in Adverse Events 1 or Adverse Events 2, indicating that no patients in the primary trial experienced any adverse events. However, in the secondary trial, there are multiple adverse events reported in Adverse Events 1, including anemia, febrile neutropenia, eye disorders - other, visual disturbance, abdominal pain, constipation, nausea, fever, pain, skin infection, alkaline phosphatase increased, and aspartate aminotransferase increased.\n\nTherefore, we can infer that there were more cases of mental health disorders, PLEUROPERICARDITIS, ATRIAL THROMBOSIS and Anemia in the secondary trial than in the primary trial."}
{"id": "215a5c4a-d90c-4500-8284-0679ce311734", "result": "The statement \"patients must have HER2- breast cancer to participate in the primary trial\" is a contradiction to the given trial information.\n\nAccording to the primary trial's eligibility criteria, patients with ErbB2(HER2)overexpressing breast cancer are eligible to participate in the trial. Therefore, patients with HER2- breast cancer can participate in the primary trial."}
{"id": "e9a4bd91-f58b-4234-9037-75e0699d1bbd", "result": "The statement \"the primary trial participants recieve less than 300mg/m^2 doses of Pralatrexate\" is entailed by the given trial information.\n\nThe Intervention section of the primary trial states that the study drug is 190 mg/m^2 for 2 to 4 weeks. Therefore, it can be inferred that the primary trial participants receive less than 300mg/m^2 doses of Pralatrexate."}
{"id": "7d52734c-0801-413d-9ae2-d190b972cde5", "result": "The statement \"The results from the secondary trial and the primary trial can be compared by changing the units from days to months\" is a contradiction to the given trial information.\n\nThe primary trial results are assessed at 8 weeks, while the secondary trial results are assessed at baseline to 6 months. The units of time are different in each trial, so the units cannot be converted from days to months. Therefore, the primary trial and secondary trial results cannot be directly compared."}
{"id": "5de9caeb-9dd5-4535-8fe3-289450d9c626", "result": "The statement \"the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with CNS Metastases than the Lapatinib Plus Capecitabine group\" is a contradiction to the given trial information.\n\nAccording to the Results section of the primary trial, the number of participants with CNS metastases was 8 in the Lapatinib Plus Capecitabine group and 12 in the Trastuzumab Plus Capecitabine group. However, this does not necessarily mean that the Trastuzumab Plus Capecitabine group had a higher percentage of patients with CNS metastases than the Lapatinib Plus Capecitabine group.\n\nTo calculate the percentage, we would need to divide the number of participants with CNS metastases by the overall number of participants analyzed. Doing so, we get:\n\n- For the Lapatinib Plus Capecitabine group: 8/251 = 3.2%\n- For the Trastuzumab Plus Capecitabine group: 12/250 = 4.8%\n\nTherefore, the Trastuzumab Plus Capecitabine group had a higher percentage of patients with CNS metastases than the Lapatinib Plus Capecitabine group, but this is not what the statement says."}
{"id": "bebfc78e-b35f-4677-8342-9567a7e795a1", "result": "The statement \"There is one case of Diarrhea in the secondary trial and none in the primary trial\" is a contradiction to the given trial information.\n\nAccording to the Results section of the primary trial, the number of participants with diarrhea was 1/373 (0.27%). However, according to the Adverse Events section of the secondary trial, the number of participants with diarrhea was 1/93 (1.08%).\n\nTherefore, the statement \"There is one case of Diarrhea in the secondary trial and none in the primary trial\" is a contradiction to the given trial information."}
{"id": "faa65e54-aa04-4595-8dae-05cf00b4c887", "result": "The statement \"Only cohort 1 patients of the primary trial are administered Ipatasertib\" is entailed by the given trial information.\n\nThe Intervention section of the primary trial states that participants in Intervention 1 received ipatasertib, while participants in Intervention 2 received placebo. Therefore, it can be inferred that only cohort 1 patients of the primary trial are administered Ipatasertib."}
{"id": "751fd763-89fa-4d52-8bda-f09b490a5e78", "result": "The statement \"there were no recorded deaths in the primary trial cohorts\" is entailed by the given trial information.\n\nAccording to the Results section of the primary trial, the number of patients event-free in the Fulvestrant + Anastrozole arm is 6/6 and in the Anastrozole arm is 7/7. Therefore, it can be inferred that there were no recorded deaths in the primary trial cohorts."}
{"id": "c40fdf91-9f81-454a-bba9-ec5c950cef6e", "result": "The statement \"One patient cohort in the primary trial received a placebo intervention\" is a contradiction to the given trial information.\n\nThe Intervention section of the primary trial states that participants in Intervention 1 received lapatinib and participants in Intervention 2 received placebo. Therefore, it can be inferred that Intervention 1 and Intervention 2 are the two cohorts in the primary trial, and one of them received a placebo intervention. However, it is not specified which cohort received the placebo intervention.\n\nThe statement should be \"One patient cohort in the primary trial received the placebo intervention\" for it to be entailed by the given trial information."}
{"id": "31105b43-832b-48bc-a78d-ee90c155ca44", "result": "The statement is entailed by the given trial information.\n\nThe primary trial eligibility section states that women must have hot flashes for 30 days prior to study registration, whereas the secondary trial eligibility section does not mention this requirement. Instead, the secondary trial eligibility section only states that female patients are eligible for the secondary trial. Therefore, the statement is entailed by the given trial information."}
{"id": "49ba06b2-576d-4db2-80b6-51673416f2ba", "result": "The statement \"the primary trial and the secondary trial measure the Percent Change in Net Influx Constant (Ki) by FLT PET in their patient cohorts\" is a contradiction to the given trial information.\n\nAccording to the Results sections of both the primary trial and the secondary trial, the primary trial measures the percent change between pre-treatment (baseline) and post-therapy PET measurements in breast tumors, whereas the secondary trial measures progression-free survival (PFS) as assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1).\n\nTherefore, the primary trial measures the Percent Change in Net Influx Constant (Ki) by FLT PET, while the secondary trial does not."}
{"id": "3cb71095-8e01-40dc-bbf5-eeffed55f354", "result": "This statement contradicts the given trial information. The primary trial eligibility section clearly states that patients with metastatic (stage IV) disease are eligible for the trial. This indicates that patients with histologically confirmed breast cancer stage I-III are eligible for the primary trial, as these stages do not include stage IV disease. Therefore, the statement is not entailed by the given trial information."}
{"id": "09fc4356-6154-427e-b710-ed5df6470aff", "result": "The statement is a contradiction to the given trial information. The Results section of the primary trial does not give information on cohort 2 patients in the AZD8931 120 mg bd arm/group. Therefore, it cannot be inferred if 50% of cohort 2 patients in the primary trial suffered Keratitis."}
{"id": "446f3c69-0de5-475c-a8e2-ff40ece90672", "result": "The statement is a contradiction to the given trial information. The Eligibility section of the primary trial does not mention anything about HER2 status as an inclusion criterion. It is true that the trial only enrolls patients with HER2 positive BC, but it does not mean that only patients with HER2+ve breast cancer are eligible for the primary trial."}
{"id": "cdadcb0a-20c5-47f7-a63a-39f5c6f26ae2", "result": "The statement is a contradiction to the given trial information. The Results section of the primary trial reports the Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel, which is the number of patients who experienced dose limiting toxicities divided by the total number of patients in the trial. The percentage of patients who suffered 0 side effects is 0.0%, which is reported for both Arm/Group Title: Neratinib 160 mg + Paclitaxel 80 mg/m and Arm/Group Title: Neratinib 240 mg + Paclitaxel 80 mg/m."}
{"id": "f0e845f9-8991-45b5-a520-51e934756f7a", "result": "The statement entails from the given trial information. The primary trial intervention involves the oral administration of Letrozole for 24 weeks, while the secondary trial intervention is based on a medical procedure, namely Sentinel Lymph Node Biopsy."}
{"id": "a0065d58-e03b-4dd0-9c81-cbbf651a6d45", "result": "The statement is false. The eligibility criteria for the primary trial include patients with any ER/PR/HER2 disease status, while the secondary trial only includes patients with ErbB2(HER2)overexpressing breast cancer. Therefore, not all patients eligible for the secondary trial will be eligible for the primary trial."}
{"id": "b2cdbcb8-de26-4a44-8a94-dd68c13f7e41", "result": "The statement contradicts the given trial information. The Eligibility section of the primary trial clearly states that an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1 is an inclusion criterion for the trial. Therefore, an ECOG score > 2 is not necessary to be eligible for the primary trial."}
{"id": "973f090a-8967-4d75-bb8e-6166c868337c", "result": "The statement does not entail from the given trial information. The Intervention section of the primary trial does not provide information about the dosage of ipatasertib or placebo administered to the cohorts. Therefore, we cannot determine if cohort 1 patients are administered higher doses of Ipatasertib and placebo than cohort 2 patients."}
{"id": "79ca2ee8-6c9c-40e6-a87c-925b50d3d3d2", "result": "The statement does not entail from the given trial information. The eligibility criteria for the primary trial do not mention anything about the presence of carcinomas in the stomach and neck areas. Therefore, it cannot be concluded that patients must have several visible carcinomas in the stomach and neck areas to be included in the primary trial."}
{"id": "1d1f57f8-85f7-448c-a4bb-15957da568fd", "result": "The statement entails from the given trial information. The Intervention section of the primary trial states that participants receive pemetrexed intravenous infusion every 14 days until complete response or disease progression. Therefore, it can be inferred that the primary trial intervention protocol will continue until patients achieve complete response or suffer disease progression."}
{"id": "9f7d476e-9db3-4c00-abe6-4c2f0160470a", "result": "The statement entails from the given trial information. The Results section of the primary trial states that the outcome measurement is pathologic complete response, and the time frame is 22 weeks. The Arm/Group Title for the intervention arm is \"Intervention Arm,\" and the arm/group description is \"Nab-paclitaxel, trastuzumab, doxorubicin, cyclophosphamide, Growth Factor Support, Surgery.\" The overall number of participants analyzed is 32, and the measure type is percentage of participants. The unit of measure is 26. Therefore, if under 30% of the primary trial patients in the intervention arm experienced pathologic complete response, the statement is true."}
{"id": "a5e388b9-da3c-437e-a6af-7ba76ad8bf1d", "result": "The statement contradicts the given trial information. The Intervention section of the primary trial states that participants in Intervention Arm 1 receive docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks, while participants in Intervention Arm 2 receive docetaxel 100 mg/m^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks. Therefore, both cohorts receive identical doses of docetaxel."}
{"id": "3adcc8fc-b76b-407a-a006-729a13f571fb", "result": "The statement contradicts the given trial information. The Intervention section of the primary trial states that participants in Intervention Arm 1 receive nivolumab and daratumumab for the treatment of triple-negative breast cancer (TNBC), while participants in Intervention Arm 2 receive nivolumab and daratumumab for the treatment of non-small cell lung cancer (NSCLC). Therefore, the interventions for the two cohorts are not identical, and the difference is not only the types of cancer that the patients have."}
{"id": "68379456-775b-463b-bfdb-d8aa42c9124b", "result": "The statement entails from the given trial information. The eligibility criteria for both the primary trial and the secondary trial specify that patients must be females with histologic or cytologic diagnosis of advanced breast cancer. Therefore, it can be inferred that patients must be female and have confirmed advanced breast cancer to be eligible for the secondary trial and the primary trial."}
{"id": "5d0ccb93-71ec-4079-92c6-d7cbf951a7bb", "result": "The statement contradicts the given trial information. The eligibility criteria for the primary trial state that patients must have received antitumoral hormonal treatment discontinued prior to enrollment, while the eligibility criteria for the secondary trial do not mention anything about endocrine therapy. Therefore, women currently undergoing endocrine therapy are not explicitly excluded from the secondary trial."}
{"id": "f04d9695-81b8-4d70-877b-59caddf901bd", "result": "The statement contradicts the given trial information. According to the primary trial Adverse Events section, no cases of dyspnea were recorded. According to the secondary trial Adverse Events section, one case of dyspnea was recorded in cohort 1 of the secondary trial. Therefore, not all recorded cases of dyspnea occurred in cohort 1 of the secondary trial."}
{"id": "f42e1874-343a-43ed-bb0c-884509c4793c", "result": "The statement entails from the given trial information. The primary trial measures the Percentage of Participants With Objective Response (OR) as its primary outcome, while the secondary trial measures Progression Free Survival (PFS), which is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Therefore, the primary trial measures the percentage of participants with objective response, while the secondary trial measures the number of participants with disease progression or death."}
{"id": "30483d7e-7703-459c-bd10-e2bd259c2a4f", "result": "The statement contradicts the given trial information. According to the primary trial Adverse Events section, two types of adverse events affected at least one patient in cohort 1: anaemia and vomiting. Therefore, there were not two types of adverse events which did not affect any of the patients in cohort 1 of the primary trial."}
{"id": "7cde9a22-a91f-4feb-892d-7cbd35f96a27", "result": "The statement entails from the given trial information. The primary trial reports the change in tumor size (CTS) from baseline to the end of cycle 2. This is measured by calculating the log ratio of tumor size at Cycle 2 to tumor size at baseline for each participant, where the tumor size is the sum of the target lesion measurements at each assessment. The results for each arm of the trial are presented as the mean (standard deviation) of the log ratio of end of Cycle 2 to baseline."}
{"id": "16c29502-4683-4087-9410-ff1b786556f5", "result": "The statement does not entail from the given trial information. According to the primary trial adverse events section, constipation was reported as an adverse event in 4.88% of participants (2/41). Therefore, constipation was not the least common adverse event in the primary trial."}
{"id": "5c975af8-6b7f-4a5d-b4a6-257c76763ce9", "result": "The statement does not entail from the given trial information. According to the primary trial Adverse Events section, there were no cases of acute myocardial infarction, cardiopulmonary failure, or supraventricular tachycardia in the primary trial. Therefore, there are no cases of these adverse events in the entire patient cohort of the primary trial. However, the secondary trial Adverse Events section shows that there were 1 case of acute myocardial infarction, 0 cases of cardiopulmonary failure, and 1 case of supraventricular tachycardia in cohort 1 of the secondary trial. Therefore, there are more cases of acute myocardial infarction, cardiopulmonary failure, and supraventricular tachycardia in cohort 1 of the secondary trial than in the entire patient cohort of the primary trial."}
{"id": "1c4e3fe3-b5fe-4ea3-8d9e-0ce1502080e7", "result": "The statement contradicts the given trial information. According to the primary trial Adverse Events section, there were 13 total AEs in cohort 1 and 12 total AEs in cohort 2. Therefore, there were not more total AEs in cohort 1 than cohort 2."}
{"id": "8e91e404-086e-4063-8d54-83d1b8ebd969", "result": "The statement entails from the given trial information. According to the primary trial Adverse Events section, there were a total of 6 adverse events in cohort 1 of the primary trial. Therefore, the proportion of patients in cohort 1 who suffered adverse events is 6/67, which simplifies to approximately 9%. Since 9% is greater than 1/6, the statement is true."}
{"id": "b8322b23-a4f6-4cba-9761-be826b509de7", "result": "The statement entails from the given trial information. The primary trial Adverse Events section reports a total of 0 cases of Eye disorders, Abdominal pain, Febrile neutropenia, and Anemia in its cohort, whereas the secondary trial Adverse Events section reports a total of 1, 1, 1, and 7 cases of Eye disorders, Abdominal pain, Febrile neutropenia, and Anemia, respectively, in its cohort. Therefore, the statement is true."}
{"id": "4519d1cf-7f78-4aa8-85d6-ac94f7eb75a3", "result": "The statement entails from the given trial information. The primary trial Adverse Events section reports a total of 59 and 69 cases of adverse events in cohorts 1 and 2, respectively. Of those, 14 and 17 cases were neutropenia, 10 and 10 cases were febrile neutropenia, and 2 and 2 cases were anemia, respectively. Additionally, 2 and 1 cases of pericardial effusion and cardiac failure congestive were reported in cohorts 1 and 2, respectively. In contrast, the secondary trial Adverse Events section reports a total of 0 cases of adverse events in cohort 1 and 1 case of diarrhea in cohort 2. Therefore, the statement is true."}
{"id": "4b97a844-8d52-48bb-8eda-ca205268f016", "result": "The statement contradicts the given trial information. The primary trial Eligibility section states that the life expectancy of a patient must be 1 year to be eligible for the trial. There is no mention of a life expectancy of 75+ years as a requirement for enrollment."}
{"id": "2a03c17f-3afe-40f1-a0db-4b876ee8c700", "result": "The statement contradicts the given trial information. The primary trial Results section states that the outcome measurement is \"Percent Change in Net Influx Constant (Ki) by FLT PET,\" while the secondary trial Results section states that the outcome measurement is \"Progression-Free Survival (PFS) as Assessed by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1).\" Therefore, the outcome measurements are not non-comparable, but rather different."}
{"id": "3ba42f68-a643-4d10-afd0-cbb358d05a6f", "result": "The statement contradicts the given trial information. The primary trial Intervention section shows that patients in Intervention 1 received BKM120 and Paclitaxel, while patients in Intervention 2 received Placebo and Paclitaxel. Therefore, patients in the primary trial did not receive higher doses of Paclitaxel than patients in the secondary trial. In fact, patients in the secondary trial received higher doses of Paclitaxel because they received an Active Breathing Coordinator in addition to Paclitaxel."}
{"id": "0a079cca-abde-42cf-9cec-a76e7a380e14", "result": "The statement entails from the given trial information. The Intervention section of the primary trial does not mention any surgery as part of the intervention for either Intervention 1 or Intervention 2. Therefore, patients in the primary trial are not required to undergo surgery as part of the intervention."}
{"id": "9c033072-5f94-4d79-af47-126d531f0d6e", "result": "The statement contradicts the given trial information. The primary trial Adverse Events section does not list any cases of holocraneal cephale or catheter-related infections, while the secondary trial Adverse Events section lists a total of 1 case of \"Medical device complication\" in each arm. Therefore, there are not more cases of holocraneal cephale and catheter-related infections in the primary trial than in the secondary trial."}
{"id": "a52b2d4f-0b06-4960-a9c3-88cb92df0980", "result": "The statement does not entail from the given trial information. The Intervention section of the primary trial states that participants in Intervention 1 received both Lapatinib and Capecitabine. It does not specify the frequency or dosage of each drug. Therefore, it is not possible to determine whether participants received Capecitabine less often than they received Lapatinib."}
{"id": "a792bbac-0e8a-4bf7-9cc5-56fad481e2fb", "result": "The statement contradicts the given trial information. The primary trial Eligibility section states that the trial is for women only, and that participants must be newly diagnosed with infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer. Therefore, Alex cannot be eligible for the trial. Eliane may be eligible for the trial if she meets all other inclusion and exclusion criteria."}
{"id": "1842904b-5371-49ee-b6f4-8831b879098b", "result": "The statement entails from the given trial information. The primary trial Adverse Events section lists Febrile Neutropenia as an adverse event, and it is reported in more than 5% of the total number of patients (11/56=19.64%)."}
{"id": "324562e6-2b61-4a07-b937-86f99689f2d5", "result": "The statement \"Diarrhoea is the most common adverse event in the primary trial, and Anaemia is the most common in the secondary trial\" contradicts the given trial information. The primary trial Adverse Events 1 lists \"Diarrhoea\" as an adverse event in 5/65 (7.69%) of the total number of patients, while the secondary trial Adverse Events 1 lists \"Anaemia\" as an adverse event in 6/472 (1.27%) of the total number of patients. Therefore, the statement is not entailed by the given trial information."}
{"id": "74e376d7-5713-43f3-93f1-9608059c9547", "result": "The statement contradicts the given trial information. The Results 1 and Results 2 sections state the number of patients who experienced complete response (CR) or partial response (PR) for Arm A and Arm B, respectively. Neither of the results show that over 86% of patients receiving the Docetaxel Then Liposomal Doxorubicin intervention suffered fatal complications. In fact, Results 2 shows that 31 (18 to 45) percentage of patients in Arm B had an objective benefit. Therefore, the statement cannot be inferred from the given trial information."}
{"id": "0e609fad-9a28-4fb6-90b6-32a731e3b02c", "result": "The statement is not entailed by the given trial information. The primary trial reports the outcome measurement as a percentage of participants, while the secondary trial reports the outcome measurement as a percentage of nodes. Therefore, it is not correct to conclude that the two trials report their results as percentages but use different units of measure."}
{"id": "236780db-9e59-4dc9-8da0-e786287011cf", "result": "The statement contradicts the given trial information. The primary trial intervention protocol involves pemetrexed treatment every 14 days until complete response or disease progression, which can last for an extended period of time beyond 14 days."}
{"id": "6d621974-c719-46df-8a50-d94e49583e33", "result": "The statement is not entailed by the given trial information. The primary trial Eligibility section states that prior treatment for breast cancer with endocrine therapy is allowed but should be discontinued at randomization. It does not state that all patients accepted into the primary trial have undergone prior treatment for breast cancer with endocrine therapy."}
{"id": "a9907a2e-254a-45ca-af50-3e44fd2f7af3", "result": "The statement contradicts the given trial information. The primary trial Adverse Events 1 and 2 list the number of cases of Neutropenia in Arm A and Arm B, respectively. Arm A has 1 case of Neutropenia out of 39 participants (2.56%), while Arm B has 1 case of Neutropenia out of 21 participants (4.76%). Therefore, it is not true that there was only one case of Neutropenia in both cohorts of the primary trial."}
{"id": "40f699a1-fbc6-40de-8e80-85b28f71632f", "result": "The statement is not entailed by the given trial information. The Results 1 section lists the number of participants in Arm A who experienced adverse events (AEs) of different grades, but it does not specify the total number of participants in Arm A. Therefore, it is not possible to determine whether most patients in the primary trial experienced a grade 1 adverse event. Additionally, the statement that \"grade 5, which only affected 8/70 patients\" is not entailed by the given trial information because it is not clear whether the 8 participants who experienced grade 5 events were all from Arm A or from both arms of the trial."}
{"id": "6499b181-7a23-4073-8459-ad46ff02b20f", "result": "The statement is not entailed by the given trial information. The Intervention section only states that participants will be treated until disease progression, but it does not specify the number of cycles of treatment that participants will receive. Therefore, it is not necessarily true that participants will receive the intervention for a total of 12 cycles (28 days)."}
{"id": "2da13cd4-7189-4f85-be4d-5c1e213ae293", "result": "The statement is not entailed by the given trial information. The most common adverse event in Arm A was febrile neutropenia, which affected 1/61 (1.64%) of participants. Additionally, non-cardiac chest pain, which is the adverse event mentioned in the statement, affected 2/61 (3.28%) of participants in Arm A, which is not less than 5%. Therefore, the statement is not entailed by the given trial information."}
{"id": "a9bb6de9-c6f8-4c99-81cd-f101cbaab387", "result": "Contradiction.\n\nThe statement \"Patients must have no radiographically confirmed metastases to the brain in order to be eligible for the primary trial\" directly contradicts the trial eligibility criteria. According to the Disease Characteristics section, patients must have histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain to be eligible for the trial. This requirement is repeated and reinforced with additional details throughout the Disease Characteristics section. Therefore, the presence of radiographically confirmed metastases to the brain is a prerequisite for participation in the trial, not a disqualifying factor."}
{"id": "7e5fd062-6ec3-480f-ab0e-e117eba2ffe7", "result": "Contradiction.\n\nThe statement \"All the primary trial patients achieved either Disappearance of all target lesions, >=30% decrease in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking\" contradicts the given trial information. The Results section states that the primary outcome measurement is Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) > 24 weeks, meaning that patients must have a clinical benefit from treatment by maintaining a stable or responding state for more than 24 weeks.\n\nIn the given data for Arm/Group Title \"Sorafenib and Anastrozole\", the overall number of participants analyzed is 35, but the text does not explicitly state that all 35 participants achieved CR, PR, or SD. Without a clear statement about the outcomes for all participants, it's not possible to infer that all patients achieved one of these outcomes."}
{"id": "016943fa-57ea-4293-8131-03292ea1836c", "result": "Entailment.\n\nThe statement \"A patient with a node positive T2 N2 M0 adenocarcinoma of the breast would be eligible for the primary trial, as would a patient with a node negative adenocarcinoma of the breast with a tumor diameter of over 2cm\" is entailed by the given trial information.\n\nAccording to the inclusion criteria, node-positive patients (T1-3, N1-2, M0) are eligible for the study. This includes patients with a node positive T2 N2 M0 adenocarcinoma of the breast.\n\nFurthermore, node-negative patients are eligible if they have at least one of the following features: tumor >2 cm, tumor >1 cm and negative estrogen receptor/progesterone receptor, malignancy grade 2-3, presence of peritumoral vascular invasion, or age <35 years. A node-negative adenocarcinoma of the breast with a tumor diameter of over 2 cm fits the first feature and would make the patient eligible for the primary trial."}
{"id": "402f0dbf-cf67-4425-b300-a0a3df4d59d3", "result": "Entailment.\n\nThe statement \"the secondary trial and the primary trial use Objective Response as the outcome measurement for their interventions\" is entailed by the given trial information.\n\nIn the primary trial, the outcome measurement for the interventions is Objective Response Rate (ORR). ORR is defined as the percentage of patients with objective response, which is measured based on the best overall response of either complete response (CR) or partial response (PR).\n\nIn the secondary trial, the outcome measurement for Cohort B is Objective Response (OR). OR is defined as complete response (CR) and partial response (PR) and was assessed according to the Response Evaluation Criteria in Solid Tumours version 1.0 (RECIST).\n\nAlthough the terms used in the primary trial (ORR) and secondary trial (OR) are slightly different, they both rely on the Objective Response, which includes both complete response (CR) and partial response (PR). The primary trial measures the percentage of patients with objective response (ORR), while the secondary trial measures the number of participants with objective response (OR). Therefore, the primary trial and the secondary trial both use Objective Response as the outcome measurement for their interventions."}
{"id": "62be4676-099f-4c42-8029-773af8fde6f7", "result": "The statement \"Patients must be bedbound or severaly disabled to participate in the primary trial\" is a contradiction.\n\nThe inclusion criteria for the primary trial mention that patients must have an ECOG performance status of <= 2, which is equivalent to a Karnofsky score of >= 60%. These criteria indicate that patients must be ambulatory and capable of performing their daily activities without significant limitation, rather than being bedbound or severely disabled. Thus, there is no mention of a requirement for patients to be bedbound or severely disabled in the inclusion criteria, making the statement a contradiction."}
{"id": "1180dd58-61b8-4c48-ab00-7d458e68c85b", "result": "The statement \"the results of the secondary trial and the primary trial report the same outcome measures\" is a contradiction.\n\nThe primary trial's results focus on the safety of external-beam PBI through the measurement of toxicities, including skin/subcutaneous or pulmonary toxicity, fat necrosis, and rib fractures on the ipsilateral treated side. The primary trial measures the number of participants that experienced each of these toxicities.\n\nThe secondary trial, however, focuses on the overall tumor response by reporting the best response of participants during treatment, specifically the number of participants who had complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). The secondary trial measures the number of participants with these responses.\n\nGiven that the primary trial focuses on the safety of the treatment as measured by toxicities, while the secondary trial focuses on the tumor response as measured by CR, PR, SD, and PD, the results of the secondary trial and the primary trial do not report the same outcome measures."}
{"id": "566bdc2d-7c4a-4547-87da-ac81447ecca8", "result": "The statement \"the primary trial results show that the Trastuzumab Plus Capecitabine group had a higher precentage of patients with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities, than the Lapatinib Plus Capecitabine group\" is a contradiction.\n\nThe primary trial results provided show the number of participants with CNS relapse, but they do not provide information on the number of participants with Grade 3 or 4 skin/subcutaneous or pulmonary toxicities in the two arms. Therefore, it cannot be determined if the Trastuzumab Plus Capecitabine group had a higher percentage of patients with these toxicities than the Lapatinib Plus Capecitabine group."}
{"id": "d310ec4e-993e-4827-8dc5-9aca053972db", "result": "The statement \"The primary trial intervention involves one drug taken orally and the secondary trial intervention is based on a medical procedure\" is a contradiction.\n\nThe primary trial intervention involves the drug Letrozole, which is taken orally by participants for a period of 24 weeks. This is indeed a drug taken orally.\n\nThe secondary trial intervention, however, does not involve any drug. Sentinel Lymph Node Biopsy is a medical procedure where a small amount of lymph nodes are removed and tested to determine whether cancer has spread to the lymph nodes. This is not a drug taken orally, but a medical procedure.\n\nTherefore, the statement \"The the primary trial intervention involves one drug taken orally and the Lapatinib Plus Capecitabine group is based on a medical procedure\" contradicts the information provided in the two interventions."}
{"id": "a5617ae4-05a3-42d0-9e14-141de5f8c010", "result": "The statement \"the secondary trial reported 1 single case of Conjunctivitis, whereas the primary trial did not report any\" is a contradiction.\n\nThe primary trial's adverse events do report a case of conjunctivitis, which is listed in the first adverse event section under Adverse Events 1. It's listed as 1/48 (2.08%). Therefore, the primary trial did report a case of conjunctivitis.\n\nIt is true, however, that the secondary trial also reported a case of conjunctivitis, as listed in Adverse Events 1. It's listed as 1/519 (0.19%). Therefore, the secondary trial did also report a case of conjunctivitis.\n\nIn conclusion, the primary trial and the secondary trial both reported cases of conjunctivitis, so the statement is a contradiction."}
{"id": "42d1fcd3-8faa-4065-bbba-42cc90ab67fb", "result": "The statement \"the secondary trial and the primary trial do not both measure the pCR of their patient cohorts\" is a contradiction.\n\nThe primary trial's results section reports the pCR of patients in the primary trial. The primary trial's outcome measurement is \"Number of Patients With Pathological Complete Response Rate\".\n\nThe secondary trial's results section does not mention the pCR of patients in the secondary trial. The outcome measurement in the secondary trial is \"Disease Free Survival\".\n\nHowever, it is not stated that the secondary trial does not measure the pCR of their patient cohort. The secondary trial's results section does not report the pCR, but it does not say that the secondary trial did not measure pCR.\n\nTherefore, it is not possible to determine if the secondary trial and the primary trial do not both measure the pCR of their patient cohorts."}
{"id": "d01fda83-5dc8-4ad5-92b8-7553dabd7046", "result": "The statement \"the outcome measurement of the primary trial is The length of time during and after the treatment, that a patient lives with the disease but it does not get worse\" is an entailment.\n\nThe primary trial's outcome measurement is \"Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen.\" The primary trial results provided show the median PFS of the Trastuzumab, Bevacizumab, and Docetaxel arm to be 14.3 months (95% CI: 9.3 to 35). Since PFS is a measure of the length of time during and after the treatment that a patient lives with the disease but it does not get worse, the outcome measurement of the primary trial is indeed the length of time during and after the treatment that a patient lives with the disease but it does not get worse."}
{"id": "985bc5a0-bc21-447f-92f1-150e23ede3f5", "result": "The statement \"All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions\" is a contradiction.\n\nThe primary trial results provided show that the outcome measurement is Complete Response (CR), Partial Response (PR), and Stable Disease (SD) > 24 weeks. CR is defined as the disappearance of all target lesions, PR is defined as a >=30% decrease in the sum of the longest diameter of target lesions, and SD is defined as a tumor that is neither growing nor shrinking.\n\nThe results do not provide information about the sum of the longest diameter of target lesions for individual patients, which would be necessary to determine if all the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions.\n\nTherefore, the statement \"All the primary trial patients had a minimum of 50% decrease in the sum of the longest diameter of target lesions\" is a contradiction."}
